Functionally defective high-density lipoprotein and paraoxonase: A couple for endothelial dysfunction in atherosclerosis

Cholesterol

Volumn 2013, Issue , 2013, Pages

  Eren, Esin ^a   Yilmaz, Necat ^b,c   Aydin, Ozgur ^b  

^a Nephrology Section   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

^c 07100 Antalya ^*  (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; TORCETRAPIB;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVITY; GENE EXPRESSION; HEART PROTECTION; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PON1 GENE; PON2 GENE; PON3 GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

EID: 84886510106     PISSN: 20901283     EISSN: 20901291     Source Type: Journal    
DOI: 10.1155/2013/792090     Document Type: Review

References (80)

1. Eren E., Yilmaz N., Aydin O., High density lipoprotein and it's dysfunction. The Open Biochemistry Journal 2012 6 78 93
2. Gordon S. M., Hofmann S., Askew D. S., Davidson W. S., High density lipoprotein: it's not just about lipid transport anymore. Trends in Endocrinology and Metabolism 2011 22 1 9 15 2-s2.0-78650519284 10.1016/j.tem.2010.10.001
3. Annema W., Tietge U. J. F., Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Current Atherosclerosis Reports 2011 13 3 257 265 2-s2.0-79955927693 10.1007/s11883-011-0175-2
4. deGoma E. M., deGoma R. L., Rader D. J., Beyond high-density lipoprotein cholesterol levels. Evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. Journal of the American College of Cardiology 2008 51 23 2199 2211 2-s2.0-44449103671 10.1016/j.jacc.2008.03.016 (Pubitemid 351754991)
5. Movva R., Rader D. J., Laboratory assessment of HDL heterogeneity and function. Clinical Chemistry 2008 54 5 788 800 2-s2.0-43449085800 10.1373/clinchem.2007.101923 (Pubitemid 351671595)
6. Mineo C., Shaul P. W., PON-dering differences in HDL function in coronary artery disease. Journal of Clinical Investigation 2011 121 7 2545 2548 2-s2.0-79960028404 10.1172/JCI57671
7. Kon V., Ikizler T. A., Fazio S., Importance of high-density lipoprotein quality: evidence from chronic kidney disease. Current Opinion in Nephrology and Hypertension. In press
8. Christiansen-Weber T. A., Voland J. R., Wu Y., Ngo K., Roland B. L., Nguyen S., Peterson P. A., Fung-Leung W.-P., Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency. American Journal of Pathology 2000 157 3 1017 1029 2-s2.0-0034490992 (Pubitemid 32109393)
9. Shah A. S., Tan L., Lu Long J., Davidson W. S., The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. Journal of Lipid Research. In press
10. Campbell S., Genest J., HDL: clinical equipoise and vascular endothelial function. Expert Review of Cardiovascular Therapy 2013 11 3 343 353
11. Riwanto M., Rohrer L., Roschitzki B., Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013 127 8 891 904
12. Mineo C., Deguchi H., Griffin J. H., Shaul P. W., Endothelial and antithrombotic actions of HDL. Circulation Research 2006 98 11 1352 1364 2-s2.0-33745369351 10.1161/01.RES.0000225982.01988.93 (Pubitemid 43948059)
13. Barter P. J., Nicholls S., Rye K.-A., Anantharamaiah G. M., Navab M., Fogelman A. M., Antiinflammatory properties of HDL. Circulation Research 2004 95 8 764 772 2-s2.0-6344253356 10.1161/01.RES.0000146094.59640.13 (Pubitemid 39390578)
14. Li D., Mehta J. L., 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. Endothelium 2003 10 1 17 21 2-s2.0-0037230876 10.1080/ 10623320303355 (Pubitemid 36355979)
15. Degoma E. M., Rader D. J., Novel HDL-directed pharmacotherapeutic strategies. Nature Reviews Cardiology 2011 8 5 266 277 2-s2.0-79955476272 10.1038/nrcardio.2010.200
16. Yilmaz N., Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Archives of Medical Science 2012 8 1 138 153 2-s2.0-84858219694 10.5114/aoms.2012.27294
17. Mackness B., Mackness M., The antioxidant properties of high-density lipoproteins in atherosclerosis. Panminerva Medica 2012 54 2 83 90
18. Mackness B., Quarck R., Verreth W., Mackness M., Holvoet P., Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 7 1545 1550 2-s2.0-33745964245 10.1161/01.ATV.0000222924.62641.aa (Pubitemid 44288981)
19. Aviram M., Introduction to paraoxonases. Journal of Lipids 2012 2012 2 687273 10.1155/2012/687273
20. Litvinov D., Mahini M Garelnabi H., Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. North American Journal of Medical Sciences 2012 4 11 523 532
21. Farid A. S., Horii Y., Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis. Lipids in Health and Disease 2012 11 92
22. Borowczyk K., Tisończyk J., Jakubowski H., Metabolism and neurotoxicity of homocysteine thiolactone in mice: protective role of bleomycin hydrolase. Amino Acids 2012 43 3 1339 1348 2-s2.0-84855368487 10.1007/s00726-011-1207-5
23. Riedmaier S., Klein K., Winter S., Paraoxonase (PON1 and PON3) polymorphisms: impact on liver expression and atorvastatin-lactone hydrolysis. Frontiers in Pharmacology 2011 2 41
24. Mendonça M. I., Dos Reis R. P., Freitas A. I., Sousa A. C., Pereira A., Faria P., Gomes S., Silva B., Santos N., Serrão M., Ornelas I., Freitas S., Araújo J. J., Brehm A., Cardoso A. A., Human paraoxonase gene polymorphisms and coronary artery disease risk. Revista Portuguesa de Cardiologia 2008 27 12 1539 1555 2-s2.0-60549108570
25. She Z.-G., Chen H.-Z., Yan Y., Li H., Liu D.-P., The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxidants and Redox Signaling 2012 16 6 597 632 2-s2.0-84856714045 10.1089/ars.2010.3774
26. Costa L. G., Vitalone A., Cole T. B., Furlong C. E., Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology 2005 69 4 541 550 2-s2.0-12744267818 10.1016/j.bcp.2004.08.027
27. Quillen E. E., Rainwater D. L., Dyer T. D., Novel associations of nonstructural Loci with paraoxonase activity. Journal of Lipids 2012 2012 7 189681 10.1155/2012/189681
28. Costa L. G., Giordano G., Furlong C. E., Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochemical Pharmacology 2011 81 3 337 344 2-s2.0-78650714512 10.1016/j.bcp.2010.11.008
29. Debord J., Bollinger J.-C., Merle L., Dantoine T., Inhibition of human serum arylesterase by metal chlorides. Journal of Inorganic Biochemistry 2003 94 1-2 1 4 2-s2.0-0037293171 10.1016/S0162-0134(02)00627-X (Pubitemid 36293409)
30. Bilen C., Beyaztaş S., Arslan O., Güler O. Ö., Investigation of heavy metal effects on immobilized paraoxanase by glutaraldehyde. Journal of Enzyme Inhibition and Medicinal Chemistry 2013 28 3 440 446
31. Sawamura T., Kakino A., Fujita Y., LOX-1: a multiligand receptor at the crossroads of response to danger signals. Current Opinions in Lipidology 2012 23 5 439 445
32. Mackness B., Turkie W., Mackness M., Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease. Archives of Medical Science 2013 9 1 8 13
33. Yilmaz N., Eren E., Erel O., Activity paraoxonase and arylesterase and its relationship to antioxidat profiles in young basketball players and sedentary controls. Medicina Sportiva 2007 11 20 26
34. Richter B., Niessner A., Penka M., Grdić M., Steiner S., Strasser B., Ziegler S., Zorn G., Maurer G., Simeon-Rudolf V., Wojta J., Huber K., Endurance training reduces circulating asymmetric dimethylarginine and myeloperoxidase levels in persons at risk of coronary events. Thrombosis and Haemostasis 2005 94 6 1306 1311 2-s2.0-29244451024 10.1160/TH05-03-0158 (Pubitemid 41819631)
35. Loued S., Berrougui H., Componova P., Extra-virgin olive oil consumption reduces the age-related decrease in HDL and paraoxonase 1 anti-inflammatory activities. British Journal of Nutrition 2013 19 1 13
36. Rosenblat M., Volkova N., Coleman R., Almagor Y., Aviram M., Antiatherogenicity of extra virgin olive oil and its enrichment with green tea polyphenols in the atherosclerotic apolipoprotein-E-deficient mice: enhanced macrophage cholesterol efflux. Journal of Nutritional Biochemistry 2008 19 8 514 523 2-s2.0-46749134310 10.1016/j.jnutbio.2007.06.007 (Pubitemid 351952321)
37. Parsaeyan N., Mozaffari-Khosravi H., Mozayan M. R., Effect of pomegranate juice on paraoxonase enzyme activity in patients with type 2 diabetes. Journal of Diabetes and Metabolic Disorders 2012 11 1 11
38. Balbir-Gurman A., Fuhrman B., Braun-Moscovici Y., Markovits D., Aviram M., Consumption of pomegranate decreases serum oxidative stress and reduces disease activity in patients with active rheumatoid arthritis: a pilot study. Israel Medical Association Journal 2011 13 8 474 479 2-s2.0-80052516984
39. Heden T. D., Liu Y., Sims L. Y., Meal frequency differentially alters postprandial triacylglycerol and insulin concentrations in obese women. Obesity 2013 21 1 123 129
40. Thomàs-Moyà E., Nadal-Casellas A., Gianotti M., Lladó I., Proenza A. M., Time-dependent modulation of rat serum paraoxonase 1 activity by fasting. Pflugers Archiv European Journal of Physiology 2007 453 6 831 837 2-s2.0-33847109339 10.1007/s00424-006-0174-2 (Pubitemid 46294939)
41. Thomàs-Moyà E., Gianotti M., Lladó I., Proenza A. M., Effects of caloric restriction and gender on rat serum paraoxonase 1 activity. Journal of Nutritional Biochemistry 2006 17 3 197 203 2-s2.0-32644456118 10.1016/j.jnutbio.2005.07.004 (Pubitemid 43247414)
42. Thomàs-Moyà E., Gianotti M., Proenza A. M., Lladó I., Paraoxonase 1 response to a high-fat diet: gender differences in the factors involved. Molecular Medicine 2007 13 3-4 203 209 2-s2.0-34250649666 10.2119/2006-00078.Thomas-Moya (Pubitemid 46944964)
43. Rubinow K. B., Vaisar T., Tang C., Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. Journal of Lipid Research 2012 53 7 1376 1383
44. Chee T. L., Rowley K., Jenkins A. J., O'Dea K., Itsiopoulos C., Stoney R. M., Su Q., Giles G. G., Best J. D., Paraoxonase activity in Greek migrants and Anglo-Celtic persons in the Melbourne Collaborative Cohort Study: relationship to dietary markers. European Journal of Nutrition 2005 44 4 223 230 2-s2.0-20944437266 10.1007/s00394-004-0514-y (Pubitemid 40869064)
45. Ustundag B., Bahcecioglu I. H., Sahin K., Duzgun S., Koca S., Gulcu F., Ozercan I. H., Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Digestive Diseases and Sciences 2007 52 8 2006 2014 2-s2.0-34347395156 10.1007/s10620-006-9251-9 (Pubitemid 47024653)
46. Besler C., Lüscher T. F., Landmesser U., Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Molecular Medicine 2012 4 4 251 268 2-s2.0-84859384527 10.1002/emmm.201200224
47. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D. M., Chroni A., Yonekawa K., Stein S., Schaefer N., Mueller M., Akhmedov A., Daniil G., Manes C., Templin C., Wyss C., Maier W., Tanner F. C., Matter C. M., Corti R., Furlong C., Lusis A. J., Von Eckardstein A., Fogelman A. M., Lüscher T. F., Landmesser U., Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. Journal of Clinical Investigation 2011 121 7 2693 2708 2-s2.0-79959919890 10.1172/JCI42946
48. Calabresi L., Gomaraschi M., Franceschini G., Endothelial protection by high-density lipoproteins: from bench to bedside. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 10 1724 1731 2-s2.0-0141988915 10.1161/01.ATV. 0000094961.74697.54 (Pubitemid 37254854)
49. Martínez-González J., Badimon L., Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Current Pharmaceutical Design 2007 13 22 2215 2227 2-s2.0-34548245085 10.2174/138161207781368774 (Pubitemid 47321572)
50. Julve J., Llaverias G., Blanco-Vaca F., Escolà-Gil J. C., Seeking novel targets for improving in vivo macrophage-specific reverse cholesterol transport: translating basic science into new therapies for the prevention and treatment of atherosclerosis. Current Vascular Pharmacology 2011 9 2 220 237 2-s2.0-79951719402 10.2174/157016111794519264
51. Assmann G., Gotto A. M. Jr., HDL cholesterol and protective factors in atherosclerosis. Circulation 2004 109 23 III8 III14 2-s2.0-2942750054 (Pubitemid 38786437)
52. Shao B., Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL. Biochimica et Biophysica Acta 2012 1821 3 490 501 2-s2.0-84857633918 10.1016/j.bbalip.2011. 11.011
53. Liu D., Ji L., Wang Y., Zheng L., Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein. Cardiovascular and Hematological Disorders Drug Targets 2012 12 2 98 105
54. Tong X., Peng H., Liu D., High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate. Cardiovascular Diabetology 2013 12 1 27
55. Liu D., Ji L., Tong X., Pan B., Han J.-Y., Huang Y., Chen Y. E., Pennathur S., Zhang Y., Zheng L., Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter a1. American Journal of Physiology 2011 301 3 C739 C748 2-s2.0-80052252850 10.1152/ajpcell.00055.2011
56. Wilkerson B. A., Grass G. D., Wing S. B., Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. Journal of Biological Chemistry 2012 287 53 44645 44653
57. Huang C. X., Zhang Y. L., Wang J. F., MCP-1 impacts reverse cholesterol transport by repressing ABCA1, ABCG1 and SR-BI throughPI3K/Akt post-translational regulation in HepG2 cells. Journal of Lipid Research 2013 54 5 1231 1240 10.1194/jlr.M032482
58. Yokoi K., Adachi H., Hirai Y., Plasma endothelin-1 level is a predictor of 10-year mortality in a general population: the Tanushimaru study. Circulation Journal 2012 76 12 2779 2784
59. Wu B. J., Chen K., Shrestha S., Ong K. L., High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3 β -hydroxysteroid-Δ24 reductase expression and inducing heme oxygenase-1. Circulation Research 2013 112 2 278 288
60. Bayrak T., Dursun P., Bayrak A., Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS. Gynecological Endocrinology 2012 28 11 874 878
61. Watanabe J., Marathe G. K., Neilsen P. O., Weyrich A. S., Harrison K. A., Murphy R. C., Zimmerman G. A., McIntyre T. M., Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. Journal of Biological Chemistry 2003 278 35 33161 33168 2-s2.0-0042858243 10.1074/jbc.M305321200 (Pubitemid 37055763)
62. Kotosa M., Shimada S., Kanda M., Plasma HDL reduces nonesterified fatty acid hydroperoxides originating from oxidized LDL: a mechanism for its antioxidant ability. Lipids 2013 48 6 569 578 10.1007/s11745-013-3779-1
63. Norata G. D., Catapano A. L., Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vascular Health and Risk Management 2005 1 2 119 129 2-s2.0-33745605249 10.2147/vhrm.1.2.119.64083
64. Mineo C., Shaul P. W., Novel biological functions of high-density lipoprotein cholesterol. Circulation Research 2012 111 8 1079 1090
65. Sugano M., Tsuchida K., Makino N., High-density lipoproteins protect endothelial cells from tumor necrosis factor- α -induced apoptosis. Biochemical and Biophysical Research Communications 2000 272 3 872 876 2-s2.0-0034674349 10.1006/bbrc.2000.2877 (Pubitemid 30420728)
66. Morel S., Frias M. A., Rosker C., James R. W., Rohr S., Kwak B. R., The natural cardioprotective particle HDL modulates connexin43 gap junction channels. Cardiovascular Research 2012 93 1 41 49 2-s2.0-84555188589 10.1093/cvr/cvr257
67. Trigatti B. L., Brunet R., How M., Modulators of protein kinase C affect SR-BI-dependent HDL lipid uptake in transfected HepG2 cells. Cholesterol 2011 2011 11 2-s2.0-79955095694 10.1155/2011/687939 687939
68. Mudau M., Genis A., Lochner A., Strijdom H., Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovascular Journal of Africa 2012 23 4 222 231
69. Bonetti P. O., Lerman L. O., Lerman A., Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 2 168 175 2-s2.0-0037324283 10.1161/01.ATV.0000051384.43104.FC (Pubitemid 36231924)
70. Yang Y., Loscalzo J., Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000 101 18 2144 2148 2-s2.0-0034625072 (Pubitemid 30253041)
71. Gomaraschi M., Baldassarre D., Amato M., Eligini S., Conca P., Sirtori C. R., Franceschini G., Calabresi L., Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-IMilano mutant. Circulation 2007 116 19 2165 2172 2-s2.0-35848948176 10.1161/CIRCULATIONAHA.107.705657 (Pubitemid 350060354)
72. Stancu C. S., Toma L., Sima A. V., Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell Tissue Research 2012 349 2 433 446
73. Speer T., Rohrer L., Blyszczuk P., Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity 2013 38 4 754 768 10.1016/j.immuni.2013.02.009
74. Marsche G., Saemann M. D., Heinemann A., Holzer M., Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacology & Therapeutics 2013 137 341 351
75. Gouédard C., Koum-Besson N., Barouki R., Morel Y., Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Molecular Pharmacology 2003 63 4 945 956 2-s2.0-0344951233 10.1124/mol.63.4.945 (Pubitemid 36369002)
76. Amar M. J. A., D'Souza W., Turner S., Demosky S., Sviridov D., Stonik J., Luchoomun J., Voogt J., Hellerstein M., Sviridov D., Remaley A. T., 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. Journal of Pharmacology and Experimental Therapeutics 2010 334 2 634 641 2-s2.0-77954930317 10.1124/jpet.110.167890
77. Saddar S., Mineo C., Shaul P. W., Signaling by the high-affinity HDL receptor scavenger receptor B type I. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 2 144 150 2-s2.0-75149149133 10.1161/ATVBAHA.109.196170
78. Yoshimoto R., Fujita Y., Kakino A., Iwamoto S., Takaya T., Sawamura T., The discovery of LOX-1, its ligands and clinical significance. Cardiovascular Drugs and Therapy 2011 25 5 379 391 2-s2.0-83055194612 10.1007/s10557-011-6324-6
79. Mineo C., Shaul P. W., Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends in Cardiovascular Medicine 2007 17 5 156 161 2-s2.0-34250223465 10.1016/j.tcm.2007.03.005 (Pubitemid 46898843)
80. Matsuo Y., Oberbach A., Till H., Impaired HDL function in obese adolescents: impact of lifestyle intervention and bariatric surgery. Obesity 2013 26 10.1002/oby.20538